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Benefit of the 70-gene profile for widely used guidelines: 
an answer to increased selection for adjuvant chemotherapy in breast cancer
The New Dutch GuidelinesAbstract 
Background
Discussion
Risk assessment for breast cancer patients differs 
substantially among the different treatment guidelines. 
The National Comprehensive Cancer Network (NCCN), 
St.Gallen, Adjuvant!Online, and Dutch 2008 guidelines are 
less restrictive in comparison to the 2004 Dutch guidelines 
and the Nottingham Prognostic Index (NPI), when selecting 
patients for adjuvant systemic treatment. 
Introduction:
Risk assessment for breast cancer patients differs substantially
 
among treatment 
guidelines. The NCCN, St.Gallen, Adjuvant!Online, and Dutch 2008 guidelines are 
less restrictive in comparison to the 2004 Dutch guidelines and Nottingham 
Prognostic Index, when selecting patients for adjuvant systemic treatment. The 
Dutch Institute for Healthcare Improvement (CBO) has introduced slight changes 
in the concept 2008 guidelines. Adjuvant systemic treatment is only advised when 
the absolute 10-years survival benefit is 5% or more. The new recommendations 
for adjuvant systemic treatment are based on survival tables used in the Adjuvant! 
software. The changes affect only node-negative patients aged >35 years: since 
2008 patients with G2/G3 tumors >1cm or every tumor >2cm are advised to 
undergo adjuvant systemic therapy, while in 2004 this was the case for tumors 
G3>1cm, G2>2cm or every tumor >3cm.
 
Patients and Methods:
Risk was assessed for 427 lymph-node negative (LNN) patients in the prospective 
RASTER-study (Bueno-de-Mesquita, 2007) and 151 LNN patients in the NEJM-
 
series (van de Vijver, 2002). Clinical risk was calculated using the 2004 and 2008 
Dutch guidelines. Genetic risk was assigned according to the result of the 
Amsterdam 70-gene signature. Survival analyses were done according to the 
univariate
 
Kaplan-Meier-method.
 
Results:
Instead of 57% in 2004, in 2008 only 24% of patients were assigned to clinical low 
risk in the RASTER study, and 141 patients (33%) changed from low to high risk 
(p<0.001). The rate of discordant findings between clinical assessment and 70-
 
gene signature increased from 30% in 2004 to 41% in 2008 (p<0.001, table 1). 
Similar results were obtained for the 151 patients of the NEJM-series (30% and 
35% discordance for the 2004 and 2008 CBO guidelines, respectively). At 10 years 
follow-up, differences between the high and low risk categories according to the 
2004, 2008 guidelines and the 70-gene profile, were best predicted by the latter: 
distant-disease-free survival (DDFS) log-rank p=0.002, p=0.11 and p<0.001 
respectively.
 
Discussion:
As adjuvant systemic treatments become more effective, guidelines become less 
restrictive, resulting in more patients being selected for adjuvant therapy. Since 
newer treatment guidelines do not better predict survival, the magnitude of the 70-
 
gene profiles benefit, which is defined as proportion of patients in whom over-
 
and 
undertreatment
 
can be avoided, depends on present guidelines for risk 
assessment and shows a remarkable increase.
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As adjuvant systemic treatments become more effective, 
guidelines become less restrictive, resulting in more 
patients being selected for adjuvant therapy. Since newer 
treatment guidelines do not better predict survival, the 
magnitude of the 70-gene profiles benefit, which is defined 
as proportion of patients in whom over-
 
and undertreatment
 
can be avoided, depends on present guidelines for risk 
assessment and shows a remarkable increase for the newer 
guidelines.
Abstract  # 1084
Introduction
Patients and Methods
The Dutch Institute for Healthcare Improvement (CBO) has 
introduced slight changes in the concept 2008 guidelines. 
The recommendations for adjuvant treatment are based 
upon survival tables used in the Adjuvant! software (1) and 
overlap substantially with the new St. Gallen
 
criteria (2).
 
Adjuvant systemic treatment is only advised when the 
absolute 10-year survival benefit is 5% or more. The 
changes affect only node-negative patients aged >35 years: 
since 2008 patients with G2/G3 tumors >1cm or every tumor 
>2cm are advised to undergo adjuvant systemic therapy, 
while in 2004 this was the case for tumors G3 >1cm, G2 
≥2cm or every tumor >3cm. Notably, in contrast to other 
guidelines regarding the hormone receptor status, in the 
2004 Dutch guidelines, adjuvant endocrine treatment was 
advised only in clinically high-risk patients with hormone-
 
receptor-positive tumors
 
in combination with chemotherapy. 
This has changed in the 2008 guidelines as follows: the 
Adjuvant! software may help in determining outcome for 
patients treated with chemotherapy and/or hormone 
therapy.
Survival: Guidelines and 70-gene profile
Risk was assessed for 427 lymph node negative patients in 
the prospective RASTER-study (3) (Bueno-de-Mesquita et al, 
2007), that was performed between 2004 and 2006 in 16 
community-based hospitals in the Netherlands as well as for 
the 151 lymph node negative patients in the NEJM-series (4) 
(van de Vijver
 
et al, 2002). Clinical risk was calculated using 
the 2004 and 2008 Dutch guidelines as well as the present 
St.Gallen guidelines and the Nottingham Prognostic Index. 
Genetic risk was assigned according to the result of the 
Amsterdam 70-gene signature (MammaPrint™). 
Survival analyses were done according to the Kaplan-Meier-
 
method.
 
Discordance
 
was measured
 
by
 
Cohen’s
 
kappa 
coefficient
 
and significance
 
for
 
discordance
 
interpreted
 
by
 
the Landis-Koch
 
method
 
(5).
Discordance: Guidelines and 70-gene profile
Instead of 57% in 2004, in 2008 only 24% of patients were 
assigned to clinical low risk in the RASTER-study 
population, and 141 patients (33%) changed from low to high 
risk (p<0.001) with a κ=0.385, suggesting only fair agreement 
between the guidelines. The rate of discordant findings 
between clinical assessment and 70-gene signature 
increased from 30% in 2004 to 41% in 2008 (p<0.001). Details 
for NPI and St.Gallen guidelines are shown in table 1. 
Similar results were obtained for the 151 patients of the 
NEJM-series: The proportion of patients assigned to clinical 
low risk was halved from 43% to 19% in the 2008 guidelines. 
With κ=0.48, suggesting moderate agreement, 36 patients 
changed from low risk to high risk in 2008.
 
The discordance 
between the 70-gene signature and the 2004 and 2008 CBO 
guidelines changed from 30% to 35% in 2008 respectively, 
with κ
 
falling from 0.386 to 0.196, suggesting now only slight 
agreement. At 10 years FU, differences between the high 
and low risk categories according to the 2004, 2008, 
St.Gallen guidelines and the 70-gene profile, were best 
predicted by the latter: distant disease-free survival (DDFS) 
log-rank p=0.002, p=0.11, p=0.12 and p<0.001 respectively.
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RASTER-study (n=427)
70-gene 
signature 
low risk
70-gene 
signature 
high risk
Discordant findings
 
n (%), kappa
Dutch 2004 Low 243 (56.9) 168 (39.3) 76 (17.8) 127 (29.7)
 
κ
 
= 0.403High 184 (43.1) 51(11.9) 132 (30.9)
Dutch 2008 Low 103 (24.1) 74 (17.3) 29 (6.8) 174 (40.8)
 
κ
 
= 0.196High 324 (75.9) 145 (34.0) 179 (41.9)
St.Gallen     Low 75 (17.6) 63 (14.8) 12(2.8) 168 (39.3)
 
κ
 
= 0.226High 352 (82.4) 156 (36.5) 196 (45.9)
NPI              Low 248(58.1) 175 (41.0) 73 (17.1) 117 (27.4)
 
κ
 
= 0.450High 179 (41.9) 44 (10.3) 135 (31.6)
Results
Table 1: 
Rates of discordant findings between the different guidelines and the Amsterdam 70-gene signature MammaPrint™. 
Risk was assessed for 427 lymph node negative patients from the RASTER-study. 
Abbreviations: n, number of patients; NPI, Nottingham Prognostic
 
Index; κ, discordance by Cohen’s kappa coefficient
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